N
BIIB icon

Natixis’s Biogen BIIB Stock Holding History

Natixis’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-40,000
Closed -$11.1M – 996
2022
Q4 		$11.1M Buy
40,000
+20,000
+100% +$5.65M 0.06% 255
2022
Q3 		$5.34M Sell
20,000
-5,065
-20% -$1.08M 0.03% 392
2022
Q2 		$5.15M Buy
+25,065
New +$5.12M 0.02% 439

Other funds holding BIIB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Natixis's BIIB Position: Q2 2026 in Review

Natixis reduced its Biogen (BIIB) stake by 47% in Q2 2026, selling an estimated $2.04M and leaving 11,907 shares worth $2.57M. The position accounts for 0.01% of the portfolio, ranked #575.

Natixis first reported a position in BIIB in Q2 2013 and has held it in 50 quarters since. The position peaked at $63.3M in Q1 2019. 1,043 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

  • Natixis held 11,907 shares of Biogen worth $2.57M as of Q2 2026.
  • Natixis sold 10,678 Biogen shares in Q2 2026, an estimated $2.04M.
  • Biogen made up 0.01% of Natixis's portfolio in Q2 2026, its #575 holding.
  • Natixis first reported a position in Biogen in Q2 2013 and has held it in 50 quarters since.
  • Natixis's Biogen position peaked at $63.3M in Q1 2019.
  • 1,043 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Natixis's 13F filing for Q2 2026, filed 13 Aug 2026.